Menu
6th CONGRESS OF THE SKIN INFLAMMATION & PSORIASIS INTERNATIONAL NETWORK

Discussed E-Posters & E-Posters

Discussed E-Posters

 

P030

HIGH AND DURABLE CLEARANCE THROUGH 52 WEEKS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

M.Gooderham *, M.Lebwohl , K.Gordon , T.Wu , H.Photowala , H.Bachelez  (Peterborough, Canada)

 

 

P031

EFFICACY OF SWITCHING TO RISANKIZUMAB COMPARED WITH CONTINUED ADALIMUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

C.Ryan *, J.Crowley , W.Valdecantos , T.Wu , K.Reich  (Dublin, Ireland)

 

 

P032

SAFETY OF CERTOLIZUMAB PEGOL IN PLAQUE PSORIASIS: POOLED 96-WEEK DATA FROM THREE PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDIES (CIMPASI-1, CIMPASI-2 AND CIMPACT)

A.Blauvelt *, B.Strober , R.Langley , S.Kavanagh , C.Arendt , M.Boehnlein , M.Lebwohl , K.Reich  (Portland, United States)

 

 

P033

THE RISK OF PARKINSON’S DISEASE IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J. H.Lee *, K.Han , H. Y.Gee  (Seoul, Korea, Republic Of)

 

 

P034

ALZHEIMER’S DISEASE RISK IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J. H.Lee *, S.-H.Lee , K.Han , M.Kim  (Seoul, Korea, Republic Of)

 

 

P035

COEXISTENCE OF ONYCHOMYCOSIS IN PSORIATIC NAILS AND ITS CORRELATION WITH NAIL PSORIATIC SEVERITY INDEX AND PSORIASIS TREATMENT

S.Carneiro *, R.Grynszpan , A.Arnóbio , M.Fernandes , M.Paixão , A.Pessoa , M.Ramos-e-Silva  (Rio de Janeiro, Brazil)

 

 

P036

ANTINUCLEAR ANTIBODIES  IN PATIENTS WITH BEHCET'S SYNDROME

K.Khalidova *, D.Porsokhonova , Y.Alimukhamedova  (Tashkent, Uzbekistan)

 

 

P037

THE ROLE OF IMMUNE DISORDERS IN THE DEVELOPMENT OF IDIOPATHIC TYPE OF

KAPOSI'S SARCOMA

 

K.Khalidova *, G.Ismailova  (Tashkent, Uzbekistan)

 

 

P038

ANALYSIS OF IMMUNOLOGICAL ASSOCIATION BETWEEN

LATENT TUBERCULOSIS INFECTION AND PSORIASIS

C. J.Park *, J. Y.Hong , J. H.Kim , J. R.Hong , H. I.Cheon , M. S.Hur , Y. W.Lee , Y. B.Choe , K. J.Ahn  (Bucheon, Korea, Republic Of)

 

 

P039

TREATMENT SWITCHING AMONG PSORIASIS PATIENTS TREATED WITH IXEKIZUMAB, SECUKINUMAB, AND ADALIMUMAB IN REAL-WORLD SETTINGS

A.Blauvelt , N.Shi , R.Burge , W. N.Malatestinic , C. R.Lew , N. M.Zimmerman , D.Amato , B.Zhu , M. J.Murage * (Indianapolis, IN, United States)

 

 

P040

WHOLE EXOME SEQUENCING-BASED APPROACH IDENTIFIED NEW SUSCEPTIBILITY LOCI FOR PSORIASIS IN KOREAN POPULATION

K.-H.Jeong *, S.-K.Kim , M. K.Shin , N. I.Kim  (Seoul, Korea, Republic Of)

 

 

P041

GENERALIZED PUSTULAR PSORIASIS IN THE SOUTH OF TUNISIA: 44CASES.

G.Hela *, B.Emna , N.Mariem , B.Noura , B.Sonia , M.Abderrahmen , M.Slaheddine , T.Hamida  (Sfax, Tunisia)

 

 

P042

IMPACT OF MIRIKIZUMAB TREATMENT ON PSORIASIS DISEASE ACTIVITY AT WEEK 52 BASED UPON PRIOR TREATMENT WITH BIOLOGIC THERAPY

P.Rich *, A.Igarashi , D.Patel , P.Klekotka , J.Li , J.Tuttle , C.Maari  (Portland, United States)

 

 

P043

OPTIMIZING ADALIMUMAB TREATMENT IN PSORIASIS WITH CONCOMITANT METHOTREXATE: A RANDOMIZED CONTROLLED TRIAL

G.Van Der Kraaij *, C.Busard , J.van den Reek , S.Menting , E.de Jong , W.de Kort , J.Lambert , P.Spuls  (Amsterdam, Netherlands)

 

 

P044

EFFICACY OF MIRIKIZUMAB (LY3074828) AFTER STRATIFYING BY BASELINE PSORIASIS SEVERITY: POST HOC ANALYSIS OF A RANDOMIZED PHASE 2 STUDY

J.Bagel *, M.Gooderham , H.Sonnergren , B.Zhu , V.Arora , P.Klekotka , A.Egeberg  (Windsor, United States)

 

 

P045

BIPE (BIOLOGICAL TREATMENTS FOR PPAEDIATRIC PSORIASIS) : A RETROSPECTIVE OBSERVATIONAL STUDY ON BIOLOGICAL DRUG SURVIVAL IN DAILY PRACTICE IN CHILDHOOD PSORIASIS

C.Phan *, A.Beauchet , A. C.Bursztejn , S.Barbarot , C.Girard , A.Lasek , S.Hadj-Rabia , C.Abasq , C.Droitcourt  , S.Mallet , A.Phan , J.-P.Lacour , E.Bourrat , G.Chaby , P.Plantin , A.Maruani , M.Piram , F.Maccari , A. C.Fougerousse , H.Barthélémy , L.Martin , L.Mery-Bossard , V.Pallure , D.Lons-Danic , E.Puzenat , M.Beylot-Barry , D.Bouilly-Auvray , F.Aubin , E.Mahé  et the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, and the Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie (Argenteuil, France)

 

 

P046

PROFILIN-1 AS A POSSIBLE BIOMARKER IN PSORIASIS

D. H.Kim *, I. J.Jeong , S. H.Baek , H. J.Lee , M. S.Yoon , T.-A.Kim  (Seongnam, Korea, Republic Of)

 

 

P047

EXPRESSION OF SIRTUIN 1 AND INTERFERON GAMMA IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH NB-UVB PHOTOTHERAPY

O.Sorour , A.Eid *, S.Elkholy , R.Ali  (Alexandria, Egypt)

 

 

P048

REAL WORLD USE OF SECUKINUMAB IN DIFFICULT TO TREAT PLAQUE PSORIASIS IN INDIAN PATIENTS: A 72 WEEK SINGLE CENTRE RETROSPECTIVE STUDY

S.Madanagobalane * (Chennai, India)

 

 

P049

CROSS-SWITCH FROM CT-P13 TO SB2 INFLIXIMAB BIOSIMILARS IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS

P.Gisondi *, C.Virga , G.Girolomoni  (Verona, Italy)

 

 

P050

FLEXIBLE ADALIMUMAB DOSING IN MODERATE TO SEVERE PSORIASIS - THERAPEUTICAL OPTION

T.Pecova *, J.Pec  (Martin, Slovakia)

 

 

P051

ASSESSING THE DIFFERENCES BETWEEN PSORIASIS PATIENTS WHO ARE ALIGNED WITH THEIR PHYSICIAN ON THEIR CURRENT DISEASE SEVERITY VERSUS PATIENTS WHO ARE MISALIGNED

M.Murage *, O.Goldblum , C.-Y.Lin , L.Renda , S.Lobosco , J.Lucas , C.Middleton , N.Korman  (Indianapolis, United States)

 

 

P052

POTENTIAL OF HIGH-FREQUENCY ULTRASONOGRAPHY IN MONITORING PSORIASIS

A. N.Boca *, R. F.Ilies , M. C.Somlea , A.Tataru  (Cluj-Napoca, Romania)

 

 

P053

EARLY TREATMENT TARGETS FOR PREDICTING LONG-TERM DERMATOLOGY LIFE QUALITY INDEX RESPONSE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: A POST HOC ANALYSIS FROM A LONG-TERM CLINICAL STUDY

L.Puig *, B.Zhu , R.Burge , D.Shrom , D.Amato , Y.Dong , W.Shen , L.Mallbris , K.Reich  (Barcelona, Spain)

 

 

P054

IXEKIZUMAB PROVIDES PERSISTENT IMPROVEMENT IN THE SYMPTOMS OF GENITAL PSORIASIS THROUGH ONE YEAR OF TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS

C.Ryan *, R.Burge , Y.Poulin , L.Spelman , A.Potts Bleakman , F. E.Yang , C. C.Bertram , L.Guenther  (Dublin, Ireland)

 

 

P055

MAINTENANCE OF RESPONSE THROUGH UP TO 3-YEARS OF CONTINUOUS GUSELKUMAB TREATMENT OF PSORIASIS IN THE VOYAGE 2 PHASE 3 TRIAL

K.Reich *, M.Song , B.Randazzo , S. Fakharzadeh , S.Li , Y.-K.Shen , C.Han , A.Armstrong , P.Foley , K. B.Gordon  (Hamburg, Germany)

 

 

P056

COMPARABLE AND CONSISTENT EFFICACY RESPONSES WITH UP TO 3 YEARS OF GUSELKUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS REGARDLESS OF PRIOR TREATMENT: POOLED ANALYSIS FROM THE VOYAGE 1 AND VOYAGE 2 TRIALS

K.Gordon , L.Guenther *, A.Pinter , Y.-B.Choe , M.Song , S.Li , S.Fakharzadeh , Y.-K.Shen , T.-F.Tsai  (Milwaukee, United States)

 

 

P057

MIR-146A EXPRESSION IN PERIPHERAL CD14+ MONOCYTES CORRELATES WITH DISEASE SEVERITY IN PATIENTS WITH PSORIATIC ARTHRITIS: AN EARLY DIAGNOSTIC BIOMARKER

C.-H.Lee *, S.-H.Lin , C.-H.Hong  (Kaohsiung, Taiwan)

 

 

P058

TIME UNTIL ONSET OF ACTION WHEN TREATING PSORIATIC ARTHRITIS: SYSTEMATIC REVIEW AND META-ANALYSIS

A.Nast *, P. A.Pham , R. N.Werner , C.Dressler  (Berlin, Germany)

 

 

P059

A STRATEGY OF MULTIDISCIPLINARY DIAGNOSIS OF PSORIATIC ARTHRITIS

C.Rincón-Pérez *, R.Montes-Cruz , L.Rodríguez-Jiménez , O.Muñoz-Monroy , B.Mota-Mondragón , G.Aguilar , M. L.Morales-Trujillo , R.Rodríguez-Romo  (Ciudad de México, Mexico)

 

 

P060

EFFICACY AND SAFETY OF PHOTOTHERAPY IN THE ERA OF TARGETED BIOLOGICAL THERAPIES.

J. M.Ortiz Salvador *, M.Saneleuterio Temporal , J.Magdaleno Tapial , A.Pérez Ferriols  (valencia, Spain)

 

 

P061

DISCONTINUATION RATES FOR BIOLOGIC THERAPIES IN MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS IN A REAL-WORLD CANADIAN PATIENT COHORT

S.Gulliver , W.Gulliver *, S.Randell  (St. John's, Canada)

 

 

P062

EVALUATION OF CARCINOGENIC RISK OF PUVA VERSUS RE-PUVA IN PSORIATIC PATIENTS

H.Mashaly *, M.Fathy Hussein , S.Hamdy , O.Shaker  (Cairo, Egypt)

 

 

P063

THE ROLE AND RELATIONSHIP OF PLASMA D-DIMER LEVEL AND AUTOLOGOUS SERUM SKIN TEST IN THE CHRONIC SPONTANEOUS URTICARIA

 

B.Park *, K.Kim , E.Hong  (Gyeonggi-do, Korea, Republic Of)

 

 

P064

WHICH ANTIPSORIATIC INDUCTION TREATMENT SEQUENCE IS THE MOST TIME-EFFECTIVE? ECONOMIC MODELLING WITH TIME INSTEAD OF MONETARY COST

M.Zidane , C.Dressler , M.Gaskins , A.Nast * (Berlin, Germany)

 

 

P065

MANAGEMENT OF PSORIASIS USING BASIC TOOLS IN RESOURCE POOR SETUP : A STUDY OF 33 PATIENTS WITH CO MORBID CONDITIONS FOLLOWED UP FOR 5 YEARS AND 3 MONTHS.

V.Singh * (DELHI, India)

 

 

P066

EXPOSURE-EFFICACY RESPONSE MODELLING OF BMS-986165, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 STUDY IN PSORIASIS

I.Girgis *, A.Chimalakonda , S.Kundu , J.Throup , S.Banerjee  (Princeton, United States)

 

 

P067

THE EFFECT OF GUSELKUMAB ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 STUDY

A. B.Gottlieb *, B.Wolf-Henning , P.Helliwell , A.Deodhar , B. Ozturk, X. L.Xu , S.Xu , Y.Wang , Y.Zhuang , E.Hsia  (New York, United States)

 

 

P068

SHORT- AND LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: AN INTEGRATED ANALYSIS

H.Bachelez *, K.Gordon , A.Blauvelt , J.Wu , R.Sinvhal , H.Photowala , J.Valdes , B.Waterhouse , M.Lebwohl , K.Reich  (Paris, France)

 

 

P069

COMPLETE CLEARANCE AND CUMULATIVE BENEFIT BY PSORIASIS AREA AND SEVERITY INDEX (PASI) FOR BRODALUMAB AND USTEKINUMAB IN AMAGINE-2 AND -3

R.Warren *, J.Hansen , V.Schultz Nielsen , L.Puig  (Salford, United Kingdom)

 

 

P070

THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PRCL-02 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC PLAQUE PSORIASIS

M.Gooderham , K. A.Papp *, R.Larouche , E.Raddad , J.Sloan-Lancaster , J.Bingham , P.Clermont , Z. P.Neeb , C.Fortier  (Waterloo, Canada)

 

 

P071

WOULD CHILDREN TREATED WITH BIOTHERAPIES IN PSORIASIS, IN REAL-LIFE PRACTICE, BE ELIGIBLE FOR PHASE III CLINICAL STUDIES? EVALUATION FROM THE BIPE COHORT

C.Phan *, A.Beauchet , A. C.Bursztejn , S.Barbarot , C.Girard , A.Lasek , S.Hadj-Rabia , C.Abasq , C.Droitcourt  , S.Mallet , A.Phan , J.-P.Lacour , E.Bourrat , G.Chaby , F.Aubin , E.Mahé  et le Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, et le Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie (Argenteuil, France)

 

 

P078

TILDRAKIZUMAB EFFECT ON CARDIOMETABOLIC RISK PROFILE IN PATIENTS WITH PSORIASIS BY METABOLIC SYNDROME STATUS: POOLED ANALYSIS FROM TWO PHASE 3 TRIALS

N. N.Mehta *, M. G.Lebwohl , A.Peserico , E.Fumero , A. B.Gottlieb , A. M.Mendelsohn , J.Myers , J.Parno , S. J.Rozzo , A.Menter  (Bethesda, United States)

 

 

P079

SUSTAINED RESPONSES OF TREATMENT BY BRODALUMAB COMPARED TO USTEKINUMAB

L.Puig *, J.Hansen , V.Schultz Nielsen , E.Laffitte  (Barcelona, Spain)

 

 

P080

SAFETY IN PATIENTS WITH LATENT TUBERCULOSIS (TB) TREATED WITH GUSELKUMAB AND ANTI-TB TREATMENTS IN THE PHASE 3 VOYAGE 1 & 2 TRIALS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS

L.Puig *, T.-F.Tsai , T.Bhutani , J.Uy , P.Ramachandran , M.Song , Y.You , M.Gooderham , M.Lebwohl  (Barcelona, Spain)

 

 

P081

EFFICACY OF RISANKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS BY BASELINE CHARACTERISTICS AND PRIOR THERAPIES

B.Strober *, W.Valdecantos , T.Zhan , J.Lambert , A.Menter  (Farmington, United States)

 

 

P082

MANAGAMENT OF SEVERE PSORIASIS WITH IL12/23 ANTAGONIST AFTER DEVELOPMENT OF TNF ANTAGONIST-INDUCED LUPUS

A.Vilkaite *, V.Kucinskiene , S.Valiukeviciene  (Kaunas, Lithuania)

 

 

P083

EXPERIENCE ON THE USE OF PHOTOTHERAPY IN THE PEDIATRIC AGE AND COMPARISON WITH ITS USE IN THE ADULT POPULATION

 

J.Magdaleno-Tapial *, J.Ortiz-Salvador , C.Valenzuela-Oñate , M.Giacaman-von Der Weth , B.Ferrer-Guillén , M.García-Legaz Martínez , Á.Martínez-Domenech , D.Subiabre-Ferrer , P.Cornejo-Marí , J.Tracy-Joseph  , A.Esteve-Martínez , A.Pérez-Ferriols  (Valencia, Spain)

 

 

 

 

E-Posters

 

 

P100

ATOPIC LABIAL PIGMENTATION: A NEW DIAGNOSTIC FEATURE IN ASIAN PATIENTS WITH ATOPIC DERMATITIS

C.-Y.Lee , I.-H.Kang , K.-H.Jeong *, N. I.Kim , M. K.Shin  (Seoul, Korea, Republic Of)

 

 

P101

ATYPICAL HAND, FOOT, AND MOUTH DISEASE

CAUSED BY COXSACKIEVIRUS A6 IN CHILDREN WITH ATOPIC DERMATITIS

I.Bae *, B. S.shin , M.Kim , C.Na , H.Choi  (Gwangju, Korea, Republic Of)

 

 

P102

TREAT TO TARGET IN PSORIASIS: A BELGIAN DEFINITION OF AN OUTCOME SCORE

L.Grine *, M.De La Brassinne , P.-D.Ghislain , T.Hillary , J.Lambert , S.Segaert , F.Willaert , J.Lambert  (Ghent, Belgium)

 

 

P103

INCIDENCE OF CARDIOVASCULAR EVENTS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS TREATED WITH TILDRAKIZUMAB: POOLED ANALYSIS FROM A PHASE 2 AND TWO PHASE 3 TRIALS

R.Bissonnette *, P.Fernández-Peñas , L.Puig , A.Peserico , E.Fumero , A.Mendelsohn , S.Rozzo , A.Menter  (Montreal, Canada)

 

 

P104

IMPROVEMENT IN ABSOLUTE PSORIASIS AREA AND SEVERITY INDEX SCORE THROUGH 3 YEARS OF CONTINUOUS TREATMENT WITH GUSELKUMAB IN THE VOYAGE 1 TRIAL

L.Puig *, K. B.Gordon , T.-F.Tsai , D.Thaci , M.Gooderham , S.Fakharzadeh , S.Li , Y.-K.Shen , K.Reich  (Barcelona, Spain)

 

 

P105

LONG-TERM SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: POOLED ANALYSIS THROUGH 148 WEEKS FROM TWO PHASE 3 TRIALS

K.Reich *, D.Thaçi , I.Pau-Charles , A.Igarashi , M.Ohtsuki , M.Lebwohl , W.Cantrell , S.Rozzo , A.Blauvelt , L.Iversen  (Hamburg, Germany)

 

 

P106

UNDERSTANDING TREATMENT EFFICACY USING PATIENT-LEVEL PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORES FROM RESURFACE 1 AND RESURFACE 2 PHASE 3 TRIALS

C.Ellis *, N.Korman , F.Murphy , L.Spelman , L.Puig , A.Mendelsohn , J.Parno , S.Rozzo , P.Yamauchi  (Ann Harbor, United States)

 

 

P107

ACHIEVING AND MAINTAINING LONG-TERM OPTIMAL IMPROVEMENTS IN PATIENT-REPORTED SYMPTOMS, SIGNS, AND QUALITY OF LIFE AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH GUSELKUMAB: 3-YEAR DATA FROM VOYAGE 1

A.Blauvelt *, C.Han , K. A.Papp , C. E.Griffiths , P.Fernandez-Penas , D. N.Adam , S.Philipp  , M.Song , Y.-K.Shen , A. B.Kimball  (Portland, United States)

 

 

P108

MAINTENANCE OF RESPONSE WITH GUSELKUMAB FOR UP TO 3 YEARS’ TREATMENT IN THE PHASE 3 VOYAGE 1 TRIAL OF PATIENTS WITH PLAQUE PSORIASIS

C. E.Griffiths *, K. A.Papp , M.Song , B.Randazzo , S.Li , Y.-K.Shen , C.Han , A.Blauvelt  (Manchester, United Kingdom)

 

 

P109

IMPACT OF QUALITY OF LIFE AFTER WITHDRAWAL AND RETREATMENT WITH IXEKIZUMAB: A POST HOC ANALYSIS OF A JAPANESE STUDY ON PATIENTS WITH PLAQUE PSORIASIS (UNCOVER-J)

H.Takahashi *, Z.Cai , R.Burge , B.Zhu , H.Torisu-Itakura , D. S.Shrom , D. A.Amato , J. Y. M.Koo  (Obihiro, Japan)

 

 

P110

THE EFFICACY OF A GAIN-SWITCHED 311-NM TI:SAPPHIRE LASER IN TREATMENT OF PALMOPLANTAR PUSTULOSIS (PPP)

Y. W.Oh , J. H.Kim , D. H.Kim , H. S.Suh , Y. S.Choi * (Ulsan, Korea, Republic Of)

 

 

P111

BENEFITS OF ACHIEVING OF PATIENT-REPORTED SYMPTOM-FREE STATUS VS PASI 100 RESPONSE: ANALYSIS FROM THE VOYAGE-2 CLINICAL TRIAL

R.Bissonnette *, T.-F.Tsai , C.Han , M.Song , S.Li , S.McElligot , E.Muser , K. B.Gordon  (Montreal, Canada)

 

 

P112

RELATIONSHIP BETWEEN PASI AND DLQI SCORES AND ANXIETY/DEPRESSION IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH BRODALUMAB IN THE AMAGINE-1 TRIAL

A.Chiricozzi *, M.Faurby , J.Hansen , V.Schultz Nielsen , J.-P.Lacour  (Pisa, Italy)

 

 

P113

CORRELATION AND DIFFERENTIATION BETWEEN THE PSORIASIS SYMPTOM INVENTORY (PSI), PSORIASIS AREA AND SEVERITY INDEX (PASI), AND DERMATOLOGY LIFE QUALITY INDEX (DLQI)

L.Iversen *, M.Faurby , V.Schultz Nielsen , M.Augustin  (Aarhus, Denmark)

 

 

P114

CONSISTENCY OF RESPONSE MAINTAINED ACROSS DEMOGRAPHIC SUBGROUPS OF PSORIASIS PATIENTS TREATED WITH GUSELKUMAB FOR UP TO 3 YEARS IN THE VOYAGE 1 AND 2 TRIALS

A.Blauvelt *, K.Reich , L.Spelman , J.Bagel , R.Bissonnette , S.Gerdes , S.Fakharzadeh , M.Song , Y.-K.Shen , K. B.Gordon  (Portland, United States)

 

 

P115

LONG-TERM EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS WHO WERE RESPONDERS AT WEEK 28: POOLED ANALYSIS THROUGH 148 WEEKS FROM TWO PHASE 3 TRIALS

D.Thaçi *, L.Iversen , I.Pau-Charles , A.Igarashi , M.Ohtsuki , S.Rozzo , M.Lebwohl , W.Cantrell , A.Blauvelt , K.Reich  (Lübeck, Germany)

 

 

P116

NAIL OUTCOME IMPROVEMENTS WITH CERTOLIZUMAB PEGOL IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALS

A. B.Gottlieb *, D.Thaçi , C.Leonardi , Y.Poulin , S.Kavanagh , M.Boehnlein , K.Reich  (New York, United States)

 

 

P117

EFFICACY OF CONTINUED CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WHO INADEQUATELY RESPOND IN THE FIRST 16 WEEKS: RESULTS FROM THE CIMPACT TRIAL

M.Augustin *, M.Lebwohl , V.Piguet , H.Sofen , A.Blauvelt , L.Peterson , C.Arendt , M.Boehnlein , R. B.Warren  (Hamburg, Germany)

 

 

P118

ASSOCIATIONS BETWEEN IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND ABSOLUTE PSORIASIS AREA AND SEVERITY INDEX SCORE: RESULTS FROM VOYAGE 2

S.Tyring *, C.Han , Y.You , D.Thaçi , M.Song , S.Fakharzadeh , L.Puig  (Webster, United States)

 

 

P119

LONG-TERM EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS WHO WERE PARTIAL RESPONDERS OR NON-RESPONDERS TO ETANERCEPT: RESULTS FROM THE RESURFACE 2 PHASE 3 TRIAL THROUGH 148 WEEKS

L.Iversen *, K.Reich , C.Griffiths , A.Peserico , A.Kimball , I.Pau-Charles , A.Blauvelt , D.Thaçi  (Aarhus, Denmark)

 

 

P120

LUPUS PERNIO WITH 5 YEARS OF DECREASED VISUAL ACUITY

W.Abdelli , F.Rebhi , M.Ben Slimane , S.Youssef , N.Doss *, K.Jaber , M. R.Dhaoui  (Tunis, Tunisia)

 

 

P121

CHILDHOOD PSORIASIS : A DESCRIPTIVE STUDY

F.Rabhi *, M.ben slimen , S.youssef , K.jaber , M. R.dhaoui  (Tunis, Tunisia)

 

 

P122

ATYPICAL PITYRIASIS ROSEA PRESENTING WITH VESICULAR LESIONS

A.Pessoa *, V.Maiolini , D.Obadia , S.Carneiro , A.Brotas  (Rio de Janeiro, Brazil)

 

 

P123

FACIAL PSORIASIS IN CHILDHOOD

F.Rabhi , W.abdelli , S.Youssef , N.doss *, K.jaber , M. R.dhaoui  (Tunis, Tunisia)

 

 

P124

LUPUS VULGARIS

M.H 15 YEAR OLD FEMALE SWEDA SYRIA

THE COMPLAIN BEGAN SEVEN YEARS AGO WITH CHRONIC ULCERS WITH FACIAL ERYTHMA AND UPPER LIP ENLARGEMENT.

N.aljebae , M.Aalamatori * (Sweda, Syrian Arab Republic)

 

 

P125

INCREASE OF CARDIOVASCULAR RISK IN THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

D.Romero-Pérez , I.Belinchón-Romero *, P.Bellot , R.Francés , F.Marco , F.Marco , J. M.Ramos  (Alicante, Spain)

 

 

P126

PERIODONTAL DISEASE IN CHILEAN PSORIATIC PATIENTS AND S100A8 MOLECULAR ANALYSIS IN GINGIVAL CREVICULAR FLUID.

F.Valenzuela *, D.Carvajal , J.Fernández , A.Fernández , C.Jimenez , M.Hernández  (Santiago, Chile)

 

 

P127

CENTRAL OBESITY IN JUVENILE PSORIASIS

F.Rabhi , I.benlagha , S.youssef , N.doss *, K.jaber , M. R.dhaoui  (Tunis, Tunisia)

 

 

P128

OVERWEIGHT IN CHILDHOOD PSORIASIS: A CASE-CONTROL STUDY

F.Rabhi , I.benlagha , K.jaber , S.youssef , S.youssef , N.doss *, K.jaber , M. R.dhaoui  (Tunis, Tunisia)

 

 

P129

CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF HIV-PSORIASIS CASES

F.Úsuga Úsuga *, M.Velásquez Lopera, O.Quirós Gómez , L. A.Correa  (Medellín, Colombia)

 

 

P130

DETERMINING SURGICAL VERSUS NONSURGICAL OPTIONS FOR AN UNKNOWN INFLAMMATORY DISORDER IN A CHARCOT FOOT PATIENT

T.Brookshier * (Pomona, United States)

 

 

P131

UPADACITINIB IMPROVED PATIENT-REPORTED SLEEP IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL

K.Reich *, M.Liu , B.Calimlim , H. D.Teixeira , J. I.Silverberg  (Hamburg, Germany)

 

 

P132

PUSTULAR PSORIASIS IN TUNISIA : A 10-YEAR REVIEW

I.Chabchoub , H.Hammami , A.Zaouak , S.Fenniche * (Tunis, Tunisia)

 

 

P133

VALIDITY OF DIAGNOSTIC CODES FOR IDENTIFICATION OF PSORIASIS PATIENTS IN KOREA

H.-J.Park *, S. P.Ham , J. H.Oh , H. J.Park , J. U.Kim , H. Y.Kim , S. Y.Jung , S. Y.Choi , J. E.Seol , H.Kim , M. S.Kim , U. H.Lee , M.Choi  (Goyang, Korea, Republic Of)

 

 

P134

COST EFFECTIVENESS ANALYSIS OF BIOLOGICS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN HONG KONG

J.Fung , W.Chan , J.Wu , H.Pang * (Pok Fu Lam, Hong Kong)

 

 

P135

HIDRADENITIS SUPPURATIVA HURLEY II/III: HISTOPATHOLOGICAL EVALUATION IN 26 PATIENTS

S.Carneiro *, G.Verardino , M.Chaves , A.Pessoa , R.Souto  (Rio de Janeiro, Brazil)

 

 

P136

EFFECTS OF SOD3-MSC IN A MURINE ATOPIC DERMATITIS-LIKE SKIN INFLAMMATION MODEL

T.-Y.Kim * (Seoul, Korea, Republic Of)

 

 

P137

MELANOMA AND SQUAMOUS CELL CARCINOMA IN PATIENT WITH SEVERE PUSTULAR PSORIASIS

F.Rabhi *, S.youssef , M.ben slimen , K.jaber , M. R.dhaoui  (Tunis, Tunisia)

 

 

P138

TNF-ALPHA, IL-6 AND IL-8 IN PATIENTS WITH IDIOPATHIC TYPE OF KAPOSI'S SARCOMA

K.Khalidova *, G.Ismailova  (Tashkent, Uzbekistan)

 

 

P139

EDUCATION FOR PATIENTS WITH PSORIASIS IN KOREA

H. J.Song * (Seoul, Korea, Republic Of)

 

 

P140

CHILHOOD PSORIASIS : A STUDY OF 306 CASES FROM SOUTH TUNISIA

M.Ben Rejeb *, F.Frikha , M.Mseddi , E.Bahloul , S.Boudaya , M.Amouri , H.Turki  (Sfax, Tunisia)

 

 

P141

TREATMENT WITH TNF-Α INHIBITOR RECTIFIES M1 MACROPHAGE POLARIZATION

FROM BLOOD CD14+ MONOCYTES IN PATIENTS WITH PSORIASIS INDEPENDENT

OF STAT1 AND IRF-1 ACTIVATION

C.-H.Hong *, C.-H.Lee , S.-H.Lin  (Kaohsiung, Taiwan)

 

 

P142

TRANSCRIPTOMIC ANALYSIS OF EARLY RESPONSE TO IXEKIZUMAB TREATMENTS IN CHINESE PSORIATIC PATIENTS

Y.Ren *, L.Liu , C.Zhu , X. Yin , M.Zheng  (Hangzhou, China)

 

 

P143

INTERACTION BETWEEN MUCOSAL AND CUTANEOUS IMMUNE RESPONSES TO STREPTOCOCCUS PYOGENES IN PSORIASIS: A ROLE FOR ANTIGEN SPECIFIC IGA AND CLA+ T CELLS

M.Ferran *, C.de Jesus , A.Chiriac , A.Celada , R. M.Pujol , L. F.Santamaria-Babi  (Barcelona, Spain)

 

 

P144

THE IL17F HIS161ARG POLYMORPHISM POTENTIALLY AFFECTS SUSCEPTIBILITY OF PSORIASIS THROUGH INCREASED PRODUCTION OF INTERLEUKIN-17F

Y. B.Choe *, J. Y.Hong , J. H.Kim , J. R.Hong , H. I.Cheon , M. S.Hur , Y. W.Lee , K. J.Ahn  (Seoul, Korea, Republic Of)

 

 

P145

CLINICAL FEATURES AND FREQUENCY OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PSORIATIC PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS

J.Youn *, J.Lee , H.Suh , M.Park , J.Ahn , Y.Youn  (Seoul, Korea, Republic Of)

 

 

P146

MANAGEMENT OF PUSTULAR PSORIASIS DURING PREGNANCY: REPORT OF 3 CASES

A.Zaouak *, O.Magdoud , S.Ben Jannet , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P147

PSORIASIS AND COMORBIDITIES

S.Miladi *, S.Boudaya  , E.Bahloul , A.Masmoudi , M.Mseddi , M.Amouri , H.Turki  (Sfax, Tunisia)

 

 

P148

CHLORPROMAZINE-INDUCED KOEBNER PHENOMENON IN PSORIASIS

S.Maghfour *, N.Nebli  et Y Soua, M Youssef, H Belhadjali, J Zili (Monastir, Tunisia)

 

 

P149

A CASE OF GENERALIZED PUSTULAR PSORIASIS RELATED TO ORAL TERBINAFINE

A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P150

PUSTULAR PSORIASIS AND TELOGEN EFFLUVIUM: WHICH IS INCRIMINATED THE DRUG OR THE DISEASE?

A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P151

PEDIATRIC GENERALIZED PUSTULAR PSORIASIS:  A SEVERE SKIN CONDITION

A.Zaouak *, O.Magdoud , S.Ben Jannet , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P152

TISSUE EXPRESSION OF AQUAPORIN 3 IN PSORIATIC PATIENTS BEFORE VS. AFTER TREATMENT WITH ORAL RETINOIDS AND PHOTOCHEMOTHERAPY

S.Ramadan , O.Abu Zeid , N.Dorgham , M.Assaf , M.Amer *, H.Mashaly  (Cairo, Egypt)

 

 

P153

THE PILOT STUDY OF HLA-CW06 ALLELE FREQUENCY IN LITHUANIAN PATIENTS WITH PLAQUE PSORIASIS

K.Židonienė *, I.Sakalauskienė , S.Valiukevičienė , V.Kučinskienė , L.Kučinskas , R.Ugenskienė , A.Vitkauskienė  (Kaunas, Lithuania)

 

 

P154

LINK BETWEEN PSORIASIS AND TUBERCULOSIS

N.Tsankov *, I.Grozdev  (Sofia, Bulgaria)

 

 

P155

A RARE CASE OF AMOXICILLIN INDUCED PSORIASIS

A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P156

ONYCHOMADESIS SECONDARY TO INFECTION AND ORAL RETINOIDS IN A PSORIATIC PATIENT

A.Zaouak *, A.Chamli , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P157

TRANSIENT PHOTOTOXIC SKIN REACTION IN PSORIATIC PATIENT TREATED WITH SELECTIVE PHOSPHODIESTERASE 4 INHIBITOR WITHOUT DISCONTINUING THE USE OF SYSTEMIC DRUGS

S.Valiukevičienė *, A.Bubilaitė , D.Stragytė  (Kaunas, Lithuania)

 

 

P158

HEPATIC AND MUSCULOSKELETAL DISEASE IN PSORIASIS

P.Gisondi *, C.virga , G.girolomoni  (VERONA, Italy)

 

 

P159

SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR (BMS-986165) IMPACT ON QUALITY OF LIFE (QOL) IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PSO) IN A PHASE 2 TRIAL AS ASSESSED BY THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)

D.Thaçi *, K.Papp , K.Gordon , A.Morita , M.Gooderham , P.Foley , R.Kisa , A.Napoli , S.Kundu , S.Banerjee  (Luebeck, Germany)

 

 

P160

A CASE OF SUICIDE IN A SEVERE PSORIASIS PATIENT EXACERBATED AFTER PHOTOTHERAPY

I.Bae *, B. S.shin , M.Kim , C.Na , H.Choi  (gwangju, Korea, Republic Of)

 

 

P161

PSORIASIS SEVERITY CALCULATION  AND NEW SPANISH COMORBIDITY SCREENING ALGORITHM EASED BY A SMARTPHONE APP. OPTIMISATION OF TIME IN DERMATOLOGIC CONSULTATION

E.Escario *, A.Escario  (ALBACETE, Spain)

 

 

P162

EFFICACY OF SECUKINUMAB IN BOTH BIOLOGIC-NAIVE OR NON-NAIVE PSORIASIS PATIENTS: POST-HOC FINDINGS FROM THE IPSI PSO STUDY

M.-A.Richard *, P.Joly , S.Aractingi , P.Auquier , S.Le Guen , E.Mahé  (Marseille, France)

 

 

P163

EVALUATION OF THE SECUKINUMAB EFFICACY IN SPECIFIC PSORIASIS LOCATIONS USING THE PSORIASIS SIMPLIFIED INDEX 

M.-A.Richard *, P.Joly , S.Aractingi , P.Auquier , S.Le Guen , E.Mahé  (Marseille, France)

 

 

P164

PSORIASIS SYMPTOM INVENTORY (PSI) TO ASSESS THE SEVERITY OF PLAQUE PSORIASIS SYMPTOMS AND DIFFERENCES IN PATIENT-REPORTED OUTCOMES BETWEEN BRODALUMAB AND USTEKINUMAB

M.Augustin *, V.Schultz Nielsen , J.Hansen , L.Iversen  (Hamburg, Germany)

 

 

P165

BIOLOGIC THERAPY OF PSORIASIS IN HAEMODIALYZED PATIENTS

S.Urbancek *, T.Pecova , K.Vorcakova , K.Martinaskova , M.Bielikova  (Banska Bystrica, Slovakia)

 

 

P166

USE OF SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN KOREA

G.-W.KIM *, D.-L.Ha , H.-S.Kim , H.-C.Ko , M.-B.Kim , B.-S.Kim  (Busan, Korea, Republic Of)

 

 

P167

RESPONSE OF SUPERIMPOSED LINEAR PSORIASIS TO ADALIMUMAB

M.Anodal *, P.Liarde , G.Pellerano , C.Chiappe  (Buenos Aires, Argentina)

 

 

P168

EFFECTIVITY OF ADALIMUMAB. A REAL-LIFE, LONG-TERM STUDY

J. M.Ortiz Salvador *, J. L.Sánchez Carazo , A.Pérez Ferriols  (Valencia, Spain)

 

 

P169

CHOLESTASIS IN PSORIASIS: A THERAPEUTIC CHALLENGE

A.Zaouak *, O.Magdoud , H.Hammami , S.Fenniche  (Tunis, Tunisia)

 

 

P170

DIAGNOSIS OF PSORIASIS FROM KOEBNER PHENOMENON

P.Liarde *, M.Anodal , G.Pellerano , C.Chiappe  (Buenos Aires, Argentina)

 

 

P171

INFECTIONS IN LIBYAN PATIENTS UNDER IMMUNOSUPPRESSIVE DRUGS

I.Almukahal *, H.Ehousana  (Benghazi, Libya)

 

 

 

P173

LOW DOSE NALTREXONE THERAPY FOR PSORIASIS: OPEN-LABEL CASE SERIES

A.Egeberg *, L.Weinstock , J.Cottel , L.Aldridge  (Copenhagen, Denmark)

 

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Ok Read more